Skip to main content

A New Era in Treating Hematologic Diseases, Crispr-Cas9 Genome Editing

From the 2021 Joint Annual Meeting (recorded 6/30/2021)
Presented by Kristin Landis-Piwowar, PhD, MLS(ASCP)

Genome editing has become a precise and efficient possibility for numerous diseases affecting most cell types. This session explains the use of CRISPR/Cas9 genome editing in the context of hematologic diseases and follows a patient enrolled the first clinical trial to “cure” sickle cell disease.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  • Describe the function of CRISPR in clinical applications
  • Detail the specific applications of CRISPR in hematology
  • Discuss potential challenges in using CRISPR technology

CE ACCREDITATION
ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of General (Hematology) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This Intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings